• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Phoenix Biotech Acquisition Corp.

    2/14/24 5:02:05 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials
    Get the next $PBAX alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-40877
    Issuer: CERO THERAPEUTICS HOLDINGS, INC.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 2201 Broadway
    Suite 705
    Oakland CALIFORNIA 94612
    Telephone number: 4,159,940,582
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    unit
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2024-02-14 By Tara Petta AVP
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PBAX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PBAX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PBAX
    SEC Filings

    View All

    Phoenix Biotech Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

    2/28/24 9:00:38 AM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    Phoenix Biotech Acquisition Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Change in Shell Company Status, Financial Statements and Exhibits, Leadership Update, Unregistered Sales of Equity Securities, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year (Amendment)

    8-K/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

    2/27/24 8:27:59 AM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    SEC Form D filed by Phoenix Biotech Acquisition Corp.

    D - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Filer)

    2/23/24 5:13:07 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    $PBAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Corey Daniel claimed ownership of 671,470 shares (SEC Form 3) (Amendment)

    3/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

    2/26/24 9:37:29 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    SEC Form 4 filed by Laporte Kathleen (Amendment)

    4/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

    2/21/24 5:57:09 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    Atwood Brian G acquired 248,735 shares (SEC Form 4) (Amendment)

    4/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Issuer)

    2/21/24 5:55:44 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    $PBAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Phoenix Biotech Acquisition Corp. and CERo Therapeutics, Inc. Announce Close of Business Combination

    Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) ("PBAX") and CERo Therapeutics, Inc., an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms ("CERo") today announced that their previously announced business combination has closed, resulting in CERo becoming a publicly-traded company. In connection with the consummation of the business combination, the combined public company was renamed "CERo Therapeutics Holdings, Inc." The shares of common stock of the combined public company have been approved for listing on the Nasdaq Global Market and are expected to commence trading under the ticker symbol "CERO" t

    2/14/24 4:48:00 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    CERo Therapeutics, Inc. and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Advancing the Development of Next Generation Engineered T Cell Therapeutics

    CERo is an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic mechanisms. Its lead product candidate is expected to enter clinical trials in 2024. Anticipated cash resources will fund the advancement of CERo's lead product candidate, CER-1236 to early clinical data in hematological oncology The transaction reflects a pre-money equity value of $50 million for CERo, pro forma equity capitalization of $145 million and is expected to provide up to $13.7 million held in trust, assuming no redemptions by current Phoenix stockholders and no additional capital raised Business combination expected to be completed

    6/5/23 8:00:00 AM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Mutually Agree to Terminate Business Combination Agreement

    SEATTLE, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Intrinsic Medicine, Inc. (Intrinsic), a therapeutics company leveraging human milk biology to transform Gut-Brain Axis (GBA) and inflammatory disorders, and Phoenix Biotech Acquisition Corp. (NASDAQ:PBAX) (PBAX), a special purpose acquisition company sponsored by Phoenix Biotech Sponsor, LLC and formed for the purpose of acquiring or merging with one or more businesses, today announced the mutual termination of their previously announced business combination agreement due to current market conditions. "Intrinsic was encouraged by the positive feedback from prospective investors regarding the attractiveness of our novel and capital-efficient appro

    12/6/22 9:18:15 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    $PBAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Phoenix Biotech Acquisition Corp. (Amendment)

    SC 13G/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    2/22/24 9:06:12 AM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13D/A filed by Phoenix Biotech Acquisition Corp. (Amendment)

    SC 13D/A - CERO THERAPEUTICS HOLDINGS, INC. (0001870404) (Subject)

    2/20/24 5:18:13 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials

    SEC Form SC 13G/A filed by Phoenix Biotech Acquisition Corp. (Amendment)

    SC 13G/A - PHOENIX BIOTECH ACQUISITION CORP. (0001870404) (Subject)

    2/8/24 12:31:58 PM ET
    $PBAX
    Consumer Electronics/Appliances
    Industrials